News

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong

Biogen Completes Acquisition of Human Immunology Biosciences

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

Biogen to Report Second Quarter 2024 Financial Results August 1, 2024

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

Biogen Announces Webcast of Annual Meeting of Stockholders

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease